Skip to main content

Prokidney Corp.

PROK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001850270

In the last 90 days, Prokidney Corp. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $99.5M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Prokidney Corp. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of PROK: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders8490+6
Shares23.1M22.9M−143.0K (−0.6%)
Value$226.1M$227.0M+$880.0K (+0.4%)

New holders (13)

Institutions that held Prokidney Corp. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to PROK in Q4 2021
InstitutionSharesValue% of portfolio
RP Investment Advisors LP538,848$5.33M0.66%
LH Capital Markets, LLC500,000$4.95M2.24%
Cowen and Company, LLC322,000$3.19M0.30%
Whitefort Capital Management, LP160,615$1.59M1.27%
Fifth Lane Capital, LP150,000$1.49M0.87%
Beryl Capital Management LLC100,000$990.0K0.05%
Aequim Alternative Investments LP99,782$988.0K0.03%
Berkley W R Corp50,000$495.0K0.03%
Sandia Investment Management LP50,000$495.0K0.08%
Bank of Nova Scotia40,000$396.0K0.00%
Schechter Investment Advisors, LLC37,253$369.0K0.03%
UBS Group AG755$7.00K0.00%
Tower Research Capital LLC (TRC)536$5.00K0.00%

Sold out (7)

Institutions that held Prokidney Corp. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of PROK in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Maven Securities LTD500,000$4.90M
Schonfeld Strategic Advisors LLC400,000$3.92M
Athanor Capital, LP400,000$3.92M
JPMorgan Chase & Co150,000$1.47M
Cohen & Co Financial Management, LLC101,414$994.0K
Omers Administration Corp40,000$392.0K
Parallax Volatility Advisers, L.P.37,685$369.0K